Associated Genetic Biomarkers
Mediator complex subunit 12 (MED12) is a gene that encodes a protein that is a member of a CDK8 protein complex that binds to a component of the preinitiation complex that functions in protein assembly. The protein encoded by this gene functions in the regulation of transcription. Missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame deletions and insertions are observed in cancers such as breast cancer, endometrial cancer, and lung cancer.
MED12 is altered in 3.51% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, prostate adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in MED12 are MED12 Mutation (3.05%), MED12 Loss (0.20%), MED12 Q2120_Q2121insPAAT (3.56%), MED12 H2116_Q2119dup (3.19%), and MED12 Amplification (0.09%) .
MED12 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains MED12 status as an inclusion criterion, 1 is phase 1 (0 open).
Trials with MED12 status in the inclusion eligibility criteria most commonly target bladder carcinoma, breast carcinoma, colorectal carcinoma, head and neck carcinoma, and lymphoma .
The most frequent alterations to serve as inclusion eligibility criteria are MED12 Loss and MED12 Mutation .
Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials with MED12 as an inclusion criteria .
Significance of MED12 in Diseases
Colorectal Carcinoma +
Non-Small Cell Lung Carcinoma +
MED12 is altered in 4.93% of non-small cell lung carcinoma patients .
MED12 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Bladder Carcinoma +
Malignant Solid Tumor +
Head And Neck Carcinoma +
MED12 is altered in 3.05% of head and neck carcinoma patients .
MED12 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) .
Ovarian Carcinoma +
Breast Carcinoma +
Pancreatic Carcinoma +
Anaplastic Astrocytoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.